BAD HOMBURG, Germany, Dec. 20,
2024 /PRNewswire/ -- Fresenius Medical Care (FME),
the world's leading provider of products and services for people
with kidney disease, will return to the top tier of the German
Stock Index, the DAX 40, as of December 27,
2024. The index represents the performance of the 40 largest
publicly traded companies listed on the Frankfurt Stock Exchange
and accounts for around 80 percent of the market capitalization of
listed stock corporations in Germany.
Fresenius Medical Care will return to the
top tier of the German Stock Index, the DAX 40, as of December 27, 2024.
Helen Giza, CEO and Chair of the
Management Board of Fresenius Medical Care AG, said: "We are
delighted to return to the DAX 40. In Germany and worldwide, the index is synonymous
with German innovative strength and entrepreneurial growth. This
recognition underscores the continuous hard work of our employees
for our patients and shareholders and is a strong testament of our
performance. Our path had been defined always very clearly to
return to the large-cap index by turning around the performance and
by successfully executing our strategy. We have delivered what we
promised, and we are very happy to be back."
Fresenius Medical Care has been currently listed in the
second-largest German stock market index, the Mid-Cap DAX (MDAX),
which tracks the 50 largest companies below the DAX 40 since
March 2023. Prior to this, the
company had been a member of the DAX since September 1999.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products
and services for individuals with renal diseases of which around
4.1 million patients worldwide regularly undergo dialysis
treatment. Through its network of 3,732 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for approx. 308,000
patients around the globe. Fresenius Medical Care is also the
leading provider of dialysis products such as dialysis machines or
dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock
Exchange (FME) and on the New York Stock Exchange (FMS).
For more information visit the company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are subject
to various risks and uncertainties. Actual results could differ
materially from those described in these forward-looking statements
due to various factors, including, but not limited to, changes in
business, economic and competitive conditions, legal changes,
regulatory approvals, impacts related to the COVID-19 pandemic
results of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care's reports filed with the
U.S. Securities and Exchange Commission. Fresenius Medical Care
does not undertake any responsibility to update the forward-looking
statements in this release.
Media contact
Christine
Peters
T +49 160 60 66 770
christine.peters@freseniusmedicalcare.com
Contact for analysts and investors
Dr. Dominik Heger
T +49 6172 609 2601
dominik.heger@freseniusmedicalcare.com
www.freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-returns-to-dax-40-index-302337459.html
SOURCE Fresenius Medical Care Holdings, Inc.